Active substanceParacetamolParacetamol
Similar drugsTo uncover
  • Apap
    pills inwards 
    YuS Pharmacy LLC     Poland
  • Daleron
    suspension inwards 
  • Daleron
    pills inwards 
  • Children's Panadol
    suspension inwards 
  • Children's Panadol
    suppositories rect. 
  • Children's Panadol
    suppositories rect. 
  • Ifimol®
    solution d / infusion 
  • Kalpol®
    suspension inwards 
  • Xoomapar
    granules inwards 
    Italfarmaco SpA     Italy
  • Panadol®
    pills inwards 
  • Panadol®
    pills inwards 
  • Paracetamol
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Paracetamol
    pills inwards 
  • Paracetamol
    suppositories rect. 
    FARMPROJECT, CJSC     Russia
  • Paracetamol
    pills inwards 
    PHARMACY 36.6, CJSC     Russia
  • Paracetamol
    pills inwards 
    ORGANICS, JSC     Russia
  • Paracetamol
    suppositories rect. 
    ALTAYVITAMINS, CJSC     Russia
  • Paracetamol
    pills inwards 
  • Paracetamol
    syrup inwards 
    ROSFARM, LLC     Russia
  • Paracetamol
    suspension inwards 
    SYNTHESIS, OJSC     Russia
  • Paracetamol
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Paracetamol
    pills inwards 
    BIOCHEMIST, OJSC     Russia
  • Paracetamol
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Paracetamol
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Paracetamol
    pills inwards 
  • Paracetamol
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Paracetamol
    pills inwards 
    ATOLL, LLC     Russia
  • Paracetamol
    pills inwards 
  • Paracetamol
    solution d / infusion 
    JODAS EKSPOIM, LLC     Russia
  • Paracetamol of Avexime
    pills inwards 
  • Paracetamol for children
    suspension inwards 
  • Paracetamol for children
    suspension inwards 
    ATOLL, LLC     Russia
  • Paracetamol Cabi
    solution d / infusion 
  • Paracetamol MS
    pills inwards 
    MEDISORB, CJSC     Russia
  • Paracetamol Rowtec
    solution d / infusion 
    ARS, LLC     Russia
  • Paracetamol-Lect
    pills inwards 
  • Paracetamol-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Paracetamol-Hemofarm
    pills inwards 
    Hemofarm AD     Serbia
  • Perfalgan
    solution d / infusion 
  • Strimol
    pills inwards 
    Natur Product Europe BV     Netherlands
  • Cefexon® D
    suppositories rect. 
    NIZHFARM, JSC     Russia
  • Efferalgan®
    pills inwards 
  • Efferalgan®
    syrup inwards 
  • Efferalgan®
    suppositories rect. 
  • Dosage form: & nbspsolution for infusions
    Composition:1.0 ml of the solution contains:
    Active substances:
    Paracetamol 10.0 mg
    Excipients: mannitol 50.0 mg, sodium hydrogen phosphate 0.25 mg, sodium hydroxide to a pH of 4.5 to 6.5, hydrochloric acid to a pH of 4.5 up to 6,5, water for injections up to 1,0 ml.
    Description:Transparent colorless or light yellow solution.
    Pharmacotherapeutic group:analgesic non-narcotic remedy
    ATX: & nbsp

    N.02.B.E   Anilides

    N.02.B.E.01   Paracetamol

    Pharmacodynamics:
    Paracetamol has an anesthetic, antipyretic and weak anti-inflammatory effect.
    Analgesic effect of paracetamol occurs within 5-10 minutes after the start infusion and reaches a maximum after 1 h; duration of action - 4-6 hours.
    Antipyretic effect of paracetamol occurs within 30 minutes after the start infusion; duration of action not less than 6 h.
    Precise mechanism of analgesic and antipyretic action of paracetamol not installed. Apparently, it includes itself is central and peripheral Components.
    It is known that paracetamol inhibits cyclooxygenase I and II predominantly in CNS, affecting the centers of pain and thermoregulation.
    In inflamed tissues cellular peroxidases are neutralized effect of paracetamol on cyclooxygenase, which explains complete absence of anti-inflammatory effect.
    Absence of influence on synthesis prostaglandins in peripheral tissues stipulates the absence from him negative influence on water-salt exchange (sodium and water retention) and the mucous membrane of the gastrointestinal tract.
    Pharmacokinetics:With a single and multiple introduction paracetamol for 24 hours in doses up to 2 g of its pharmacokinetics bears linear character.
    Bioavailability of paracetamol when administered in the form of infusion in a dose of 1 g does not differ from bioavailability 2 g of propetamol (contains 1 g of paracetamol). Maximum the concentration of paracetamol in the blood plasma is reached 15 minutes after intravenous infusion at a dose of 1 g and is 30 μg / ml. The distribution volume in adults is 1 l / kg. Paracetamol weakly binds to plasma proteins. Penetrates through the blood-brain barrier; 20 minutes after intravenous infusion of 1 g of the drug in the cerebrospinal fluid, a high concentration of paracetamol (about 1.5 μmol / ml) is detected.In adults paracetamol is metabolized mainly in the liver with the formation of glucuronides and sulfates. A small part (4%) of paracetamol is metabolized by cytochrome P450 to form an active intermediate metabolite (N- acetylbenzoquinonimine), which in normal conditions fast is neutralized by reduced glutathione and is excreted in the urine after binding to cysteine ​​and mercapturic acid. However, with a massive overdose, the amount of this toxic metabolite increases. The half-life in adults is 2.7 hours, in children 1.5-2 hours, and the total clearance is 18 liters per hour. Paracetamol is excreted mainly in the urine; 90% of the accepted dose is excreted by the kidneys within 24 hours, mainly in the form of glucuronide (60-80%) and sulfate (20-30%). Less than 5% is displayed unchanged.In severe renal failure (creatinine clearance <10-30 ml / min) excretion of paracetamol is somewhat slowed down, and the half-life is 2-5.3 hours.
    The rate of elimination of glucuronide and sulfate in patients with severe renal failure is 3 times lower than in healthy volunteers.
    The pharmacokinetics of paracetamol do not change in elderly patients; in children, only the half-life of plasma is different, which is somewhat shorter in comparison with adults (1.5-2 h). In addition, children under 10 years paracetamol more deduced in the form of sulphate, and not glucuronide, which is typical for adult patients. At the same time, the total clearance of paracetamol and its metabolites in patients of all age groups is the same.
    Indications:Short-term treatment of moderate pain intensity (especially in postoperative period) and short-term fever stopping, when intravenous administration is clinically justified or impossible to introduce in other ways.
    Contraindications:

    Hypersensitivity to paracetamol or propacetamol hydrochloride

    (prodrug of paracetamol) or any other component of the preparation.

    Severe hepatic insufficiency.Children up to 3 months.
    Carefully:Severe renal insufficiency (creatinine clearance <30 ml / min), benign hyperbilirubinemia (in t.ch. Gilbert's syndrome, viral hepatitis, alcoholic liver damage), chronic alcoholism, chronic malnutrition due to low levels of glutathione in hepatocytes, anorexia, bulimia, cachexia, hypovolemia, dehydration, old age, deficiency of glucose-6-phosphate dehydrogenase.
    Pregnancy and lactation:

    The clinical experience of intravenous paracetamol is limited. However, according to epidemiological data on the ingestion of paracetamol in therapeutic doses, undesirable effects on the course of pregnancy or the health of the fetus and the newborn have not been revealed. An overdose of paracetamol during pregnancy does not increase the risk of congenital malformations.

    Research on reproductive toxicity in animals with intravenous drug forms of paracetamol were not performed. Studies with paracetamol ingestion did not reveal a teratogenic or fetotoxic potential.

    In this regard, the drug should be used during pregnancy only if the expected benefit exceeds the possible risk for the mother and fetus, strictly observing the dosing regimen and the timing of treatment.

    After ingestion of paracetamol, it penetrates into breast milk in small amounts. No adverse effects on the child have been reported. Paracetamol can be used in period of the breast Feeding if the expected benefit for the mother exceeds the risk to the child.

    Dosing and Administration:

    Dosing regimen

    Unintentional excess of recommended doses can lead to a serious impairment of liver function, including fatalities. When determining the dose, individual risk factors for hepatotoxicity in the patient, including hepatic insufficiency, chronic alcoholism, chronic eating disorders, dehydration, should also be considered.

    Calculation of doses is based on the patient's body weight.

    Weight bodies the patient

    Single entry

    dose

    Input

    amount

    Maximum are admissibleth amount introduction of

    ***

    Maximum dose**

    10 kg *

    7,5 mg / kg

    0,75 ml / kg

    7.5 ml

    30 mg / kg

    > 10 kg

    ≤ 30 kg

    15 mg / kg

    1,5 ml / kg

    49 ml

    60 mg / kg, but not more than 2 g

    > 33 kg

    ≤ 50 kg

    15 mg / kg

    1,5 ml / kg

    75 ml

    60 mg / kg, but not more than 3 g

    > 50 kg, if there are risk factors for hepatotoxicity

    1 g

    100 ml

    100 ml

    3 grams

    > 50 kg, in the absence of risk factors for hepatotoxicity

    1 g

    100 ml

    100 ml

    4 grams

    * The safety and efficacy of the drug in premature infants is not established.

    ** The maximum daily dose, taking into account the use of all drugs containing paracetamol or propacetamol.

    *** With a lower body weight, it is recommended to inject a low volume of the drug. The interval between the introduction should not be less than 4 hours. More than 4 introductions per day is not allowed. The interval between administration for severe renal failure should not be less than 6 hours.

    Special patient groups

    In case of severe impairment of kidney function (creatinine clearance <30 ml / min), the interval between injections should be at least 6 hours.

    In case of violations of liver function in adults and patients with chronic alcoholism, eating disorders or dehydration, the daily dose should not exceed 3 g.

    Dose adjustments in elderly patients are not required.

    Method of administration

    Intravenous (iv) single infusion for 15 minutes.

    The drug should not be mixed in one vial for infusions with other medications.

    Infusion should be performed immediately after opening the vial; The unused residue of the drug is destroyed.Before starting the infusion, the vial with the drug should be carefully inspected for lack of visible mechanical particles and discoloration of the solution.

    Additional dilution is possible with 0.9% sodium chloride solution or 5% dextrose solution, in addition for 1/10 part of the original volume. The diluted solution should be used within an hour after preparation, including the infusion time. Before starting the infusion, the vial with diluted drug should be carefully inspected for lack of visible mechanical particles and discoloration of the solution.

    For infusion, use a needle with a diameter of 0.8 mm, which is injected into the vial in a place marked on the rubber stopper, holding the bottle strictly vertically. As in the case of other solutions for infusions supplied in glass containers, Avoidance of air embolism should be particularly cautious, especially at the end of the infusion, regardless of which vein is injected.

    When the drug is administered to children and adolescents, the vial with the drug can not be suspended as an infusion vessel due to a small amount of contents.

    To avoid mistakes in the calculation of doses for children weighing less than 10 kg, it is recommended to specify the volume for a single injection in milliliters (ml),In this category of patients, the injected volume of the drug should not exceed 7.5 ml per infusion.

    In order to measure the dose of the drug taking into account the child's body weight and the required volume, a 5 or 10 ml syringe should be used.

    The volume of the preparation necessary for the patient's administration should be extracted from the vial and diluted in a 0.9% solution of sodium chloride or 5% dextrose solution in a ratio of 1:10 (one volume of the preparation in nine volumes of the dilution solution) and administered within 15 minutes.

    Side effects:The incidence of side effects is given in accordance with the following scale: very often> 10%; often> 1% and <10%); infrequently> 0.1% and <1%; rarely> 0.01% and <0.1 %; very rare <0.01%.

    From the skin: very rarely - redness of the skin, itching, rashes on the skin and mucous membranes (usually erythematous or urticaria).

    From the liver and bile ducts: rarely - increased activity of "liver" enzymes, usually without the development of jaundice.

    From the cardiovascular system: rarely - lowering blood pressure; very rarely - tachycardia.

    On the part of the organs of hematopoiesis: very rarely - thrombocytopenia.

    General: rarely - malaise.

    The following side effects were also noted in the post-marketing use of the drug, however, their frequency was not established:

    Allergic reactions: reactions hypersensitivity, anaphylactic shock, anaphylaxis, angioedema.

    From the liver and biliary tract: fulminant hepatitis, necrosis

    liver, liver failure, increased activity of "liver" enzymes.

    From the gastrointestinal tract: nausea, vomiting.

    Local reactions: soreness and burning sensation at the injection site.
    Overdose:

    Overdose may lead to intoxication, especially in elderly patients, children, patients with liver diseases (caused by chronic alcoholism), in patients with eating disorders, as well as in patients taking inductors of microsomal liver enzymes, at which fulminant hepatitis, hepatic insufficiency, cholestatic hepatitis, cytolytic hepatitis, in the cases indicated above - sometimes with a fatal outcome.

    The clinical picture of acute overdose develops within 24 hours after taking paracetamol.

    Symptoms: gastrointestinal disorders (nausea, vomiting, decreased appetite, abdominal discomfort and / or abdominal pain), pale skin. With the simultaneous administration of 7.5 grams or more to adults or children over 140 mg / kg, cytolysis of hepatocytes occurs with complete and irreversible necrosis of the liver, development hepatic insufficiency, metabolic acidosis and encephalopathy, which can lead to coma and death. 12-48 hours after the introduction of paracetamol, an increase in the activity of "hepatic" transaminases, lactate dehydrogenase, bilirubin concentration and a decrease in the prothrombin content was noted.

    Clinical symptoms of liver damage are manifested after 2 days after drug overdose and reach a maximum of 4-6 days.

    Treatment:

    - Immediate hospitalization.

    - Determination of the quantitative content of paracetamol in blood plasma before treatment at the earliest possible time after an overdose;

    - Introduction donators SH-groups and precursors of the synthesis of glutathione-methionine and TM-acetylcysteine-within 10 hours after an overdose.

    - The need for additional therapeutic interventions (further administration of methionine, iv administration N-acetylcysteine) is determined depending on the concentration of paracetamol in the blood, as well as on the time elapsed after its administration.

    - Symptomatic treatment.

    - Hepatic tests should be performed at the beginning of treatment and then every 24 hours.

    In most cases, the activity of liver transaminases normalizes within 1-2 weeks. In very serious cases, liver transplantation may be required.

    Interaction:Probenecid almost halves the clearance of paracetamol, inhibiting the process of its conjugation with glucuronic acid. With simultaneous application, consideration should be given to reducing the dose of paracetamol.
    Inducers of microsomal liver enzymes (eg, ethanol, phenytoin, barbiturates, isoniazid, rifampicin, anticoagulants, zidovudine, amoxicillin + clavulanic acid) increase the production of hydroxylated active metabolites, which makes it possible to develop severe intoxication with small overdoses.
    Ethanol promotes the development of acute pancreatitis.
    Long-term use of barbiturates reduces the effectiveness of paracetamol. Inhibitors of microsomal liver enzymes (incl. cimetidine) reduce the risk of hepatotoxic effects.
    Long-term simultaneous use of paracetamol and other non-steroidal anti-inflammatory drugs (salicylamide) increases the risk of developing analgesic nephropathy and renal papillary necrosis, the onset of the terminal stage of renal failure.
    Simultaneous long-term use paracetamol in high doses and salicylates increases the risk of cancer kidney or bladder. Salicylamide increases half-life paracetamol.
    Simultaneous application of paracetamol in infusions (4 g / day, not less than 4 days) and indirect anticoagulants can lead to a slight change international normalized relationship (INR). It should be controlled INR during treatment and during the week after stopping infusions of paracetamol.
    Special instructions:It is recommended to transfer the patient to oral taking painkillers drugs, as soon as such a opportunity.
    The risk of liver damage increases when the recommended doses are exceeded (in including simultaneous application of preparation Paracetamol and other preparations containing paracetamol), a also in patients with chronic alcoholism.
    To avoid the risk of overdose, do not simultaneous reception is recommended preparation and other paracetamol medications. Distorts the results of quantitative determination of uric acid in the plasma.
    Form release / dosage:Solution for infusion 1%.
    Packaging:50 ml or 100 ml of the drug per bottle from low density polyethylene.
    1. Each vial with instructions application put in a pack of cardboard.
    2. Each bottle together with a disposable system for intravenous administration of solutions with a built-in ventilation barrier against bacteria "Eurodrype" and instructions for use are placed in a cardboard pack.
    Storage conditions:In the dark place, with temperature not higher than 25 ° С.
    Keep out of the reach of children.
    Shelf life:2 years.
    Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001964
    Date of registration:28.12.2012
    The owner of the registration certificate:ARS, LLC ARS, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp02.10.2015
    Illustrated instructions
      Instructions
      Up